White & Case advises Bridgepoint on sale of Diaverum to M42

Press Release
1 min read

Global law firm White & Case LLP has advised Bridgepoint on its disposal of Diaverum to M42, a newly created healthcare joint venture between G42 Healthcare and Mubadala Health.

"We have supported Bridgepoint and Diaverum over a period of several years culminating in Diaverum's successful sale," said White & Case partner Steven Worthington, who led the Firm's deal team. "This transaction demonstrates the strength and depth of our M&A capabilities, which enable us to execute the most complex, high profile international transactions."

Diaverum is a leading global renal healthcare and dialysis company that provides essential, life-sustaining dialysis treatments to patients in around 440 clinics across 23 countries. It is a Bridgepoint portfolio company.

The acquisition of Diaverum is a strategic investment for M42, which aims to leverage both companies' clinical excellence and leading technological expertise to expand healthcare services and healthtech solutions across new and existing markets.

The deal, which is subject to customary regulatory approvals, is expected to close in the second half of 2023.

The White & Case team which advised on the transaction was led by partner Steven Worthington (Abu Dhabi and London) with support from associates Joseph Bradley, Jean Renaldy (both London) and Hugh Brunjes (Abu Dhabi).

Press contact
For more information please speak to your local media contact.